癌症患者中扩增和过表达的预后价值：一项系统评价和荟萃分析。

Prognostic Values of Amplification and Overexpression in Cancer Patients: A Systematic Review and Meta-analysis.

作者信息

Zhao Haiyue, Wang Junling, Zhang Yong, Yuan Ming, Yang Shuangxiang, Li Lisong, Yang Huilin

机构信息

Center of Reproduction and Genetics, Suzhou Municipal Hospital, Affiliated Suzhou Hospital of Nanjing Medical University, 26 Daoqian Road, Suzhou, Jiangsu 215002, China.

Department of Gynaecology, Huangshi Maternity And Children's Health Hospital Edong Healthcare Group, No.80 Guilin Road, Huangshi 43500, China.

出版信息

J Cancer. 2018 Jun 14;9(13):2397-2407. doi: 10.7150/jca.24179. eCollection 2018.

A number of studies revealed that copy number amplification and overexpression (on mRNA or protein expression level) were associated with prognosis of diverse cancers, however, the results were inconsistent among studies. So we conducted this systematic review and meta-analysis to investigate the prognostic values of amplification and overexpression in cancer patients. PubMed, Cochrane library, Embase, CNKI and WanFang database (last update by February 15, 2018) were searched for literatures. A total of 20 studies were included and 5 survival assessment parameters were measured in this study, which included overall survival (OS), progression free survival (PFS), recurrence free survival (RFS), cancer specific survival (CSS) and distant metastasis free survival (DMFS). Pooled analyses showed that amplification might predict poor OS (HR=1.59, 95% CI: 1.05-2.40, =0.027) rather than PFS (HR=1.49, 95% CI: 0.83-2.67, =0.177) and RFS (HR=0.982, 95% CI: 0.2376-4.059, =0.9801) in various cancers; overexpression significantly correlated with poor OS (HR=1.52, 95% CI: 1.05-2.20, =0.027), PFS (HR=1.20, 95% CI: 1.07-1.34, =0.001) and DMFS (HR=1.62, 95% CI: 1.09-2.40, =0.017) rather than RFS (HR=1.68, 95% CI: 0.81-3.50, =0.164) and CSS (HR=1.54, 95% CI: 0.74-3.18, =0.246). On the whole, these results indicated amplification and overexpression were associated with poor survival of patients with cancer, suggesting that might be an effective prognostic signature for cancer patients.

多项研究表明，拷贝数扩增和过表达（在mRNA或蛋白质表达水平上）与多种癌症的预后相关，然而，各研究结果并不一致。因此，我们进行了这项系统评价和荟萃分析，以研究扩增和过表达在癌症患者中的预后价值。检索了PubMed、Cochrane图书馆、Embase、中国知网和万方数据库（截至2018年2月15日的最新数据）中的文献。本研究共纳入20项研究，并测量了5个生存评估参数，包括总生存期（OS）、无进展生存期（PFS）、无复发生存期（RFS）、癌症特异性生存期（CSS）和无远处转移生存期（DMFS）。汇总分析显示，在各种癌症中，扩增可能预示OS较差（HR=1.59，95%CI：1.05-2.40，P=0.027），而非PFS（HR=1.49，95%CI：0.83-2.67，P=0.177）和RFS（HR=0.982，95%CI：0.2376-4.059，P=0.9801）；过表达与较差的OS（HR=1.52，95%CI：1.05-2.20，P=0.027）、PFS（HR=1.20，95%CI：1.07-1.34，P=0.001）和DMFS（HR=1.62，95%CI：1.09-2.40，P=0.017）显著相关，而非RFS（HR=1.68，95%CI：0.81-3.50，P=0.164）和CSS（HR=1.54，95%CI：0.74-3.18，P=0.246）。总体而言，这些结果表明扩增和过表达与癌症患者的不良生存相关，提示其可能是癌症患者有效的预后指标。